第一作者机构：[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
Song Zhenchuan,Li Ruoyang.Eribulin plus pyrotinib In trastuzumab-resistant HER2-positive advanced breast cancer: A single-arm, multicenter phase II trial (EPIC trial)[J].JOURNAL OF CLINICAL ONCOLOGY.2025,43(16_SUPPL):doi:10.1200/JCO.2025.43.16_suppl.1031.
APA：
Song, Zhenchuan&Li, Ruoyang.(2025).Eribulin plus pyrotinib In trastuzumab-resistant HER2-positive advanced breast cancer: A single-arm, multicenter phase II trial (EPIC trial).JOURNAL OF CLINICAL ONCOLOGY,43,(16_SUPPL)
MLA：
Song, Zhenchuan,et al."Eribulin plus pyrotinib In trastuzumab-resistant HER2-positive advanced breast cancer: A single-arm, multicenter phase II trial (EPIC trial)".JOURNAL OF CLINICAL ONCOLOGY 43..16_SUPPL(2025)
医学